CFT8634

CFT8634 is an orally bioavailable PROTAC BRD9 targeted degrader based on the E3 ubiquitin ligase CRBN mechanism. CFT8634 can be used for the study of synovial sarcoma and SMARCB1-deficient solid tumors (Pink: BRD9 ligand (HY-169988) ; Blue: E3 ligase ligand (HY-169989) ; Black: linker (HY-169991) . CFT8634 is a heterobifunctional molecule that binds to BRD9 at one end and recruits CRBN at the other end, which can inhibit the growth of tumor cells that depend on BRD9. CFT8634 can be used for the study of SMARCB1-related cancers (such as synovial sarcoma and malignant rhabdoid tumor) [1][2][3][4].

Product Specifications

CAS Number

[2704617-96-7]

UNSPSC

12352005

Target

Epigenetic Reader Domain; PROTACs

Type

Reference compound

Related Pathways

Epigenetics; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cft8634.html

Purity

98.10

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C(C1=CC(OC)=C(C(OC)=C1)CN2CC(F)([C@@H](N3CCN(C4=C(C=C(C=C4)N[C@@H]5C(NC(CC5)=O)=O)F)CC3)CC2)F)=CN6C)=C(C)C6=O

Molecular Formula

C37H45F3N6O5

Molecular Weight

710.79

References & Citations

[1]Zeng S, et al. Current advances and development strategies of orally bioavailable PROTACs. Eur J Med Chem. 2023 Dec 5;261:115793.|[2]Jackson, et al. "Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers." Cancer Research 82.12_Supplement (2022) : ND09-ND09.|[3]Poling, et al. "CFT8634, a clinical stage BRD9 Bi DAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide." Blood 142 (2023) : 6594.|[4]Poling, et al. "CFT8634, a BRD9 BiDAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone." Cancer Research 84.6_Supplement (2024) : 6046-6046.